Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...
Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...